// App-Quantinova.ai

: Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG).

Researchers

Presenter

  • Arjun Vasant Balar

Principal Investigators

  • Girish S. Kulkarni

  • Edward M. Uchio

  • Joost Boormans

  • Loic Mourey

  • Laurence Eliot Miles Krieger

  • Eric A. Singer

  • Dean F. Bajorin

  • Ashish M. Kamat

  • Petros Grivas

  • Ho Kyung Seo

  • Hiroyuki Nishiyama

  • Badrinath R. Konety

  • Kijoeng Nam

  • Ekta Kapadia

  • Tara L. Frenkl

  • Ronald De Wit

Medical Centers

  • Perlmutter Cancer Center NYU Langone, New York, NY

  • Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

  • UC Irvine Health, Orange, CA

  • Erasmus University Medical Center, Rotterdam, Netherlands

  • Institut Universitaire du Cancer de Toulouse, Toulouse, France

  • Royal North Shore Hospital, Northern Cancer Institute, St Leonards, NSW, Australia

  • Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • University of Washington, Seattle, WA

  • National Cancer Center, Goyang-si, Korea, Republic of.

  • University of Tsukuba, Tsukuba, Japan

  • University of Minnesota, Minneapolis, MN

  • Merck & Co., Inc., Kenilworth, NJ

Locations

  • United States

  • Canada

  • Netherlands

  • France

  • Australia

  • Japan

  • Republic of South Korea

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02625961

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved